NPO Microgen is actively engaged in the modernization of existing enterprises in accordance with international GMP standards (Good Manufacturing Practice). The companies in Ufa, Perm, Tomsk are actively upgrading their equipment. In 2014, the Tomsk branch of NPO Virion commissioned the production building completely meeting the international quality standards.
Great attention is paid to partnership relations – in 2014 strategically important agreements with the world’s leading manufacturers of immunobiological products were signed for the transfer and exchange of technologies for the production of high-quality and effective medicines.
NPO Microgen pays great attention to the development of new innovative products that would be quite competitive with products of foreign manufactures. At the beginning of 2014, the company launched the first domestic botulinum neurotoxin type A Relatox in the Russian market.
Specialists of NPO Microgen have created the first Enterobacter bacteriophage drug in the world practice. It will help to treat acute intestinal diseases, infections of the biliary and urinary tracts, purulent skin lesions, meningitis, sepsis, hospital-acquired infections. We are planning to launch it in the consumer market in 2016.
And, of course, we pay great attention to vaccines that are included in the National Calendar of Preventive Vaccinations or will be included in its extended version.
NPO Microgen has prepared production sites to manufacture the first domestic thiomersal-free Td vaccine (low-dose adsorbed tetanus and diphtheria vaccine). This vaccine free from organic mercury compounds is identical to thiomersal-based preparations for its efficacy, safety, physical and chemical properties and complies with national and international requirements to the quality of vaccines. In addition, a thiomersal-free inactivated pertussis suspension has also been successfully registered. Tetanus toxoid, low-dose diphtheria toxoid, TDP and TDP-HepB vaccines free from this preservative are being prepared for registration.
The combined diphtheria, tetanus and pertussis (TDaP) vaccine, well known to all parents, has received a new component for the prevention of Hepatitis B and Hib and has become pentavalent. The new vaccine was developed in the Perm branch of NPO Microgen. At present, two associated pentavalent DTP-HepB-Hib vaccines containing the whole-cell pertussis vaccine (wP) and acellular pertussis vaccine (aP) are ready for clinical trials.
NPO Microgen has begun clinical studies of the combined measles-mumps-rubella (MMR) vaccine Vaktrivir.
Specialists of NPO Microgen pay great attention to the development and clinical studies of new vaccines: clinical studies of the combined measles-mumps-rubella vaccine Vaktrivir have been successfully completed. The Ufa branch of NPO Microgen has developed and begun the production of the new effective influenza vaccine Sovigripp.
